DCF Advisers’s Lineage Cell Therapeutics LCTX Stock Holding History

DCF Advisers’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-107,751	Closed	-$54.1K	–	93
2024 Q4	$54.1K	Hold	107,751	–	–	0.03%	84
2024 Q3	$97.5K	Hold	107,751	–	–	0.04%	93
2024 Q2	$107K	Hold	107,751	–	–	0.06%	88
2024 Q1	$159K	Buy	107,751 +13,000	+14%	+$14.7K	0.08%	75
2023 Q4	$103K	Buy	94,751 +12,000	+15%	+$13.1K	0.06%	74
2023 Q3	$97.6K	Buy	82,751 +67,751	+452%	+$92.2K	0.05%	90
2023 Q2	$21.1K	Buy	+15,000	New	+$20.7K	0.01%	89
2022 Q2	–	Sell	-53,000	Closed	-$82K	–	82
2022 Q1	$82K	Sell	53,000 -32,000	-38%	-$49.7K	0.04%	65
2021 Q4	$208K	Sell	85,000 -2,000	-2%	-$4.68K	0.08%	69
2021 Q3	$219K	Buy	87,000 +12,500	+17%	+$32.1K	0.1%	75
2021 Q2	$212K	Buy	74,500 +53,500	+255%	+$138K	0.08%	89
2021 Q1	$49K	Buy	+21,000	New	+$50.4K	0.02%	103

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCF Advisers's LCTX Position: Q1 2025 in Review

DCF Advisers sold out of Lineage Cell Therapeutics (LCTX) in Q1 2025, closing a stake of 107,751 shares — an estimated $54.1K sold.

DCF Advisers first reported a position in LCTX in Q1 2021 and held it in 12 quarters. The position peaked at $219K in Q3 2021. 127 funds tracked by Wall St. Rank hold LCTX as of Q1 2025.

DCF Advisers reported no remaining Lineage Cell Therapeutics position as of Q1 2025 after selling out during the quarter.
DCF Advisers sold 107,751 Lineage Cell Therapeutics shares in Q1 2025, an estimated $54.1K.
DCF Advisers first reported a position in Lineage Cell Therapeutics in Q1 2021 and held it in 12 quarters.
DCF Advisers's Lineage Cell Therapeutics position peaked at $219K in Q3 2021.
127 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2025.

Based on DCF Advisers's 13F filing for Q1 2025, filed 9 May 2025.